肠道菌群在非酒精性脂肪性肝病中的研究进展

摘要/Abstract

摘要： 非酒精性脂肪性肝病(NAFLD)是目前世界范围内最常见的慢性肝脏疾病,可导致肝硬化、肝细胞癌等严重后果。NAFLD发病涉及肝脏脂肪堆积、炎症反应、肝细胞变性坏死等一系列病理过程,然而其发病机制仍不明确。越来越多的证据表明,肠道菌群与NAFLD发病机制之间存在着复杂的联系。肠道菌群可通过改变肠道通透性、生成毒性代谢产物等机制促进NAFLD的发生。肠道菌群丰度及组成的变化可作为NAFLD无创诊断及分期的新型标志物,益生菌及粪便菌群移植在NAFLD治疗方面亦具疗效。

关键词: 非酒精性脂肪肝病, 肠道菌群, 机制, 临床应用

辜雪莲, 李俊峰, 毛小荣. 肠道菌群在非酒精性脂肪性肝病中的研究进展[J]. 肝脏, 2021, 26(12): 1418-1420.

参考文献

[1] Younossi Z M, Koenig A B, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016, 64:73-84.
[2] Estes C, Anstee Q M, Arias-Loste M T, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol, 2018, 69:896-904.
[3] Younossi Z, Stepanova M, Ong J P, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol, 2019, 17:748-755.
[4] Milosevic I, Vujovic A, Barac A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases: a review of the literature. Int J Mol Sci, 2019, 20:395.
[5] Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature, 2011, 473:174-180.
[6] Loomba R, Seguritan V, Li W, et al. Gut microbiome-based metagenomic signature for non-invasive detection of advanced fibrosis in human nonalcoholic fatty liver Disease. Cell Metab, 2017, 25:1054-1062.e5.
[7] Lelouvier B, Servant F, Païssé S, et al. Changes in blood microbiota profiles associated with liver fibrosis in obese patients: a pilot analysis. Hepatology, 2016, 64:2015-2017.
[8] Tsai M-C, Liu Y-Y, Lin C-C, et al. Gut microbiota dysbiosis in patients with biopsy-proven nonalcoholic fatty liver disease: a cross-sectional study in taiwan. Nutrients, 2020, 12:820.
[9] Sharpton S R, Ajmera V, Loomba R. Emerging role of the gut microbiome in nonalcoholic fatty liver disease: from composition to function. Clin Gastroenterol Hepatol, 2019, 17:296-360.
[10] Tripathi A, Debelius J, Brenner D A, et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol, 2018, 15:397-411.
[11] Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology, 2009, 49:1877-1887.
[12] Mouries J, Brescia P, Silvestri A, et al. Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development. J Hepatol, 2019, 7:1216-1228.
[13] Qi X, Yang M, Stenberg J, et al. Gut microbiota mediated molecular events and therapy in liver diseases. World J Gastroenterol, 2020, 26:7603-7618.
[14] Ponziani F R, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology, 2019, 69:107-120.
[15] Ji Y, Yin Y, Li Z, et al. Gut Microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease (NAFLD). Nutrients, 2019, 11: 1712.
[16] Hu H, Lin A, Kong M, et al. Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. J Gastroenterol, 2020, 55:142-158.
[17] Zhao S, Jang C, Liu J, et al. Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate. Nature, 2020, 579:586-591.
[18] Rau M, Rehman A, Dittrich M, et al. Fecal SCFAs and SCFA-producing bacteria in gut microbiome of human NAFLD as a putative link to systemic T-cell activation and advanced disease. United European Gastroenterol J, 2018, 6:1496-1507.
[19] Zhou D, Chen Y-W, Zhao Z-H, et al. Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression. Exp Mol Med, 2018, 50:1-12.
[20] Jin C J, Sellmann C, Engstler A J, et al. Supplementation of sodium butyrate protects mice from the development of non-alcoholic steatohepatitis (NASH). Br J Nutr, 2015, 114: 1745-1755.
[21] Ye J, Lv L, Wu W, et al. Butyrate protects mice against methionine-choline-deficient diet-induced non-alcoholic steatohepatitis by improving gut barrier function, attenuating inflammation and reducing endotoxin levels. Front Microbiol, 2018, 9: 1967.
[22] Zhu L, Baker S S, Gill C, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH. Hepatology, 2013, 57:601-609.
[23] Yuan J, Chen C, Cui J, et al. Fatty liver disease caused by high-alcohol-producing klebsiella pneumoniae. Cell Metab, 2019, 30:675-688.e7.
[24] Chaudhry K K, Samak G, Shukla P K, et al. ALDH2 deficiency promotes ethanol-induced gut barrier dysfunction and fatty liver in mice. Alcohol Clin Exp Res, 2015, 39:1465-1475.
[25] Zhu R, Baker S S, Moylan C A, et al. Systematic transcriptome analysis reveals elevated expression of alcohol-metabolizing genes in NAFLD livers. J Pathol,2016,238:531-542.
[26] Abdelmegeed M A, Choi Y, Godlewski G, et al. Cytochrome P450-2E1 promotes fast food-mediated hepatic fibrosis. Sci Rep, 2017, 7:39764.
[27] Arias N, Arboleya S, Allison J, et al. The Relationship between choline bioavailability from diet, intestinal microbiota composition, and its modulation of human diseases. Nutrients, 2020, 12:2340.
[28] Cho C E, Aardema N D J, Bunnell M L, et al. Effect of choline forms and gut microbiota composition on trimethylamine--oxide response in healthy men. Nutrients, 2020, 12: 2220.
[29] Wahlström A, Sayin S I, Marschall H-U, et al. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab, 2016, 24:41-45.
[30] Park M Y, Kim S J, Ko E K, et al. Gut microbiota-associated bile acid deconjugation accelerates hepatic steatosis in ob/ob mice. J Appl Microbiol, 2016, 121:800-810.
[31] Sydor S, Best J, Messerschmidt I, et al. Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC. Clin Transl Gastroenterol, 2020, 11:e00131.
[32] Alexander M, Loomis A K, Van Der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med, 2019, 17:95.
[33] Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers. J Hepatol, 2018, 68:305-315.
[34] Oh T G, Kim S M, Caussy C, et al. A universal gut-microbiome-derived signature predicts cirrhosis. Cell Metab, 2020, 32:878-888.e6.
[35] Craven L, Rahman A, Nair Parvathy S, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol, 2020, 115:1055-1065.
[36] Zhou D, Pan Q, Shen F, et al. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep, 2017, 7:1529.
[37] Eslamparast T, Poustchi H, Zamani F, et al. Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr, 2014, 99:535-542.